PLUR - Rasio utang marang kapitalisasi buku pluri-biotech.com

Logo grafis Pluri (PLUR)

Premium pricing for placental therapy is driving stock growth, as evidenced by the financial leverage ratio based on book capitalization. However, Middle Eastern conflicts are undermining stability, and the environmental profile is constrained by bio-waste disposal. The current value of 0.00 represents the debt load indicator, demonstrating the balance between the financial independence of Pluri Inc. (PLUR) and the pace of its business expansion.

PLUR (Pluri) riwayat Utang marang nilai buku saka 28.04.2023 nganti 27.10.2026
Barang utama Pluri

This ratio determines the proportion of financial liabilities to equity, measuring the company's actual debt load. An increase in this value signals an overheated financing structure and heightened default risks. By analyzing the current relationship between debt and balance sheet capital, an investor assesses the sustainability of business scaling. For Pluri Inc. (PLUR), this is critical when maintaining energy-dependent bioreactors in Israel. Monitoring this metric confirms the company's ability to support costly cell therapy infrastructure.

Pesaing Pluri Inc. (PLUR)

Utang-utang marang kapitalisasi buku ASND (Ascendis Pharma A/S)|madrigalpharma.com - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Corcept Therapeutics Incorporated (CORT)|RYTM: Rasio utang marang aset resik|AKRO (Akero Therapeutics Inc) - Rasio utang marang kapitalisasi buku|Metsera Therapeutics (MTSR) - Utang marang nilai buku|MLTX (MoonLake Immunotherapeutics) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku crinetics.com (CRNX)|NewAmsterdam Pharma Company N.V. (NAMS) - Utang marang nilai buku|Rasio utang marang aset resik SLNO (Soleno Therapeutics Inc)|Amicus Pharma - Rasio utang marang kapitalisasi buku|Utang marang nilai buku 89bio Pharma ETNB|AGIO (Agios Pharmaceuticals) - Utang-utang marang kapitalisasi buku|structuretx.com (GPCR) - Utang-utang marang nilai buku|MDXG - Utang marang nilai buku|Rezolute Inc (RZLT) - Utang marang modal buku|LXRX (Lexicon Pharma) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku MBX Corp|Utang-utang marang kapitalisasi buku Altimmune, Inc. (ALT)|Rasio utang marang kapitalisasi buku AARD (aardvarktherapeutics.com)|SGMT: Rasio utang marang kapitalisasi buku|BioAge Labs - Utang-utang marang nilai buku|BMEA - Rasio utang marang kapitalisasi buku|QNCX - Rasio utang marang kapitalisasi buku|Fractyl Health, Inc. - Utang-utang marang kapitalisasi buku|VTVT (vTv Therapeutics) - Utang-utang marang aset resik|ATPC: Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik SYBX|Rasio utang marang kapitalisasi buku LPCN (Lipocine Corp)|Utang marang nilai buku MTNB (matinasbiopharma.com)|Spruce Biosciences, Inc. (SPRB) - Rasio utang marang kapitalisasi buku|galecto.com - Rasio utang-utang marang kapitalisasi buku|CTCX - Rasio utang marang kapitalisasi buku|Lumos Pharma Inc (LUMO) - Rasio utang marang kapitalisasi buku|ONVO: Utang marang nilai buku|RDUS (Radius Pharmaceuticals) - Utang-utang marang kapitalisasi buku